hMLH1、hMSH2、hMSH6在散发性结直肠癌中的表达状态与其临床病理特征的关系  

Expression of hMLHl,hMSH2 or hMSH6 in Sporadic Colorectal Cancer and Relationship of It's Expression to Clinicopathologic Parameters

作　　者：于鹏飞[1] 顾国利[1] 魏学明[1] 李明[2] 顾晋 

机构地区：[1]安徽医科大学空军临床医院空军总医院普通外科,北京100142 [2]北京大学肿瘤医院结直肠外科,北京100142

出　　处：《中国普外基础与临床杂志》2015年第5期581-585,共5页Chinese Journal of Bases and Clinics In General Surgery

基　　金：首都市民健康项目培育课题(编号:Z131100004013021)~~

摘　　要：目的探讨错配修复蛋白h MLH1、h MSH2和h MSH6在散发性结直肠癌(SCRC)中的表达情况及其与SCRC临床病理参数之间的关系。方法选取空军总医院普通外科和北京大学肿瘤医院结直肠外科2008年3月至2012年3月期间收治的SCRC患者263例,所有病例均经组织学证实且术前均未接受放化疗。采用免疫组织化学SP法检测263例SCRC患者肿瘤组织中h MLH1、h MSH2、h MSH6蛋白表达缺失情况,并分析其表达缺失与患者临床病理参数的关系。结果 263例SCRC患者肿瘤组织中h MLH1蛋白表达缺失率为13.3%(35/263),h MSH2蛋白表达缺失率为12.2%(32/263),h MSH6蛋白表达缺失率为28.9%(76/263),h MLH1/h MSH2表达共同缺失率为3.4%(9/263),h MLH1/h MSH6表达共同缺失率为10.2%(27/263),h MSH2/h MSH6表达共同缺失率为6.8%(18/263),h MLH1/h MSH2/h MSH6表达共同缺失率为3.4%(9/263)。h MSH1蛋白表达缺失率在高分化腺癌组织中明显高于中分化腺癌和低分化、黏液腺癌(P<0.01);h MSH2蛋白表达缺失率在直径>5 cm的肿瘤组织中明显高于直径≤5 cm的肿瘤组织(P<0.05);h MSH6蛋白表达缺失率在男性患者中明显高于女性患者(P<0.01),且在淋巴结转移少的肿瘤组织中明显高于淋巴结转移较多的肿瘤组织(P<0.01)。结论 h MLH1、h MSH2、h MSH6在SCRC中的表达缺失并不少见,且其表达缺失与SCRC患者临床病理参数的关系也明显不同于林奇综合征。因此,h MLH1、h MSH2、h MSH6在SCRC发生、发展中的作用可能也有别于林奇综合征。Objective To detect the expression of hMLH1, hMSH2 or hMSH6 protein in sporadic colorectal carcinoma （SCRC） and analyze the relationship of its expression to dinicopathologic parameters of patients with SCRC. Methods Two hundred and sixty-three patients with SCRC were studied, who underwent surgery in the Department of General Surgery, the Air Force General Hospital; and the Department of Colorectal Surgery, Beijing Cancer Hospital from March 2008 to March 2012. All the patients were diagnosed by histological examination without chemoradiotherapy before operation. Immunohistochemistry was used to detect the hMLHHI, hMSH2 or hMSH6 protein expression in the tumor tissues from 263 cases of SCRC. The relationship of its expression to clinicopathologic parameters was analyzed. Results The loss rates of hMLH1, hMSH2, and hMSI--I6 expressions in the tumor tissues from 263 patients with SCRC were 13.3% （35/263）, 12.2% （32/263）, and 28.9% （76/263）, respectively. The loss rates of hMLHH1/hMSH2, hMLH1/ hMSH6, hMSH2/hMSH6, and hMLH1/hMSH2/hMSH6 expressions were 3.4% （9/263）, 10.2% （27/263）, 6.8% （18/263）, and 3.4% （9/263） corresponding. The loss rate of hMLH1 expression in the high differentiated adenocarcinoma tissues was significantly higher than that of the moderate to low differentiated adenocarcinoma or mucous carcinomas tissues （P〈0.01）, The loss rate of hMLH2 expression in the tissues of tumor size more than 5 cm was significantly higher than that in the tissues of tumor size less than 5 cm （P〈O.05）. The loss rate of hMSH6 expression in the male patient was significantly higher than that of the female patient （P〈0.01） and which in the tumor tissues of less lymph node metastasis was significantly higher than that in the tissues of the more lymph node metastasis （P〈O.O 1）. Conclusions The hMLH 1, hMSH2, or hMSH6 gene expression deletion is common in SCRC and the relation with the clinical pathology of SCRC is obviously different from Lynch syndrome. Therefore, the

关 键 词：错配修复基因 散发性结直肠癌 林奇综合征 

分 类 号：R735.34[医药卫生—肿瘤]